IL-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage

Details for Australian Patent Application No. 2009321740 (hide)

Owner Klinikum der Universitat Regensburg

Inventors Mack, Matthias

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2009321740

PCT Pub. Number WO2010/063488

Priority 08021114.7 04.12.08 EP

Filing date 4 December 2009

Wipo publication date 10 June 2010

International Classifications

A61K 31/395 (2006.01) - having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

Event Publications

16 June 2011 PCT application entered the National Phase

  PCT publication WO2010/063488 Priority application(s): WO2010/063488

8 September 2011 Amendment Made

  The nature of the amendment is: Amend the name of the inventor to read Mack, Matthias and Bruhl, Hilke

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009321745-Oral dosage forms of bendamustine

2009321728-Solid dosage forms of bendamustine